{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:01:54Z","timestamp":1791464514962,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-17-13237"],"award-info":[{"award-number":["ESR-17-13237"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.chest.2026.04.040","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:20:50Z","timestamp":1778196050000},"page":"1024-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predicting Clinical Response to Benralizumab Using CT Imaging"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5209","authenticated-orcid":false,"given":"Arnaud","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Felicia","family":"Beclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vachier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Pahus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Nogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Boulhais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria","family":"Lahmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Volpato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-8042","authenticated-orcid":false,"given":"Joana","family":"Pissarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lafaye de Micheaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Bommart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2026.04.040_bib1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.chest.2026.04.040_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"issue":"10056","key":"10.1016\/j.chest.2026.04.040_bib4","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000444799","article-title":"A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan","volume":"169","author":"Park","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"issue":"25","key":"10.1016\/j.chest.2026.04.040_bib6","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2026.04.040_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"10.1016\/j.chest.2026.04.040_bib8","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2026.04.040_bib11","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti\u2013IL-5 receptor \u03b1 antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.chest.2026.04.040_bib12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"159","key":"10.1016\/j.chest.2026.04.040_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0186-2020","article-title":"Structure and function of small airways in asthma patients revisited","volume":"30","author":"Van Den Bosch","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"143","key":"10.1016\/j.chest.2026.04.040_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0010-2016","article-title":"Personalised medicine in asthma: from curative to preventive medicine","volume":"26","author":"Guilleminault","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2016.11.009","article-title":"Using imaging as a biomarker for asthma","volume":"139","author":"Trivedi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.chest.2026.04.040_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/jcm14020321","article-title":"Efficacy assessment of biological treatments in severe asthma","volume":"14","author":"Laorden","year":"2025","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.chest.2026.04.040_bib18","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/nm.2971","article-title":"Computed tomography\u2013based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression","volume":"18","author":"Galb\u00e1n","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaci.2019.01.014","article-title":"Functional CT imaging for identification of the spatial determinants of small-airways disease in adults with asthma","volume":"144","author":"Bell","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.chest.2026.04.040_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201511-2219OC","article-title":"Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease","volume":"194","author":"Bhatt","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib21","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2021.01.029","article-title":"Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3","volume":"148","author":"Krings","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-042220-015902","article-title":"The pathology of asthma: what is obstructing our view?","volume":"18","author":"Aegerter","year":"2023","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"5","key":"10.1016\/j.chest.2026.04.040_bib23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaip.2025.01.010","article-title":"Mucus plug score predicts clinical and pulmonary function response to biologic therapy in patients with severe asthma","volume":"13","author":"G\u00f6tschke","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.chest.2026.04.040_bib24","first-page":"183","article-title":"Staging in rhinosinusitus","volume":"31","author":"Lund","year":"1993","journal-title":"Rhinology"},{"key":"10.1016\/j.chest.2026.04.040_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1388585","article-title":"A clinical study on the relationship between chronic rhinosinusitis and bronchial asthma","volume":"11","author":"Kang","year":"2024","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti\u2013IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1067\/mai.2001.111593","article-title":"Rhinosinusitis in severe asthma","volume":"107","author":"Bresciani","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.chest.2026.04.040_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2026.04.040_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhn.2002.121022","article-title":"Psychometric and clinimetric validity of the 20-item Sino-Nasal Outcome Test (Snot-20)","volume":"126","author":"Piccirillo","year":"2002","journal-title":"Otolaryngol Neck Surg"},{"issue":"5","key":"10.1016\/j.chest.2026.04.040_bib30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.chest.2026.04.040_bib31","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma management and prevention. 2025. Global Initiative for Asthma website. Accessed April 8, 2026. https:\/\/ginasthma.org\/wp-content\/uploads\/2025\/05\/GINA-Strategy-Report_2025-WEB-WMS.pdf"},{"issue":"12","key":"10.1016\/j.chest.2026.04.040_bib32","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/all.12275","article-title":"EAACI position statement on asthma exacerbations and severe asthma","volume":"68","author":"Custovic","year":"2013","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.chest.2026.04.040_bib34","article-title":"How to develop a more accurate risk prediction model when there are few events","volume":"351","author":"Pavlou","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02264-2024","article-title":"What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study","volume":"65","author":"Bourdin","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2026.04.040_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"10.1016\/j.chest.2026.04.040_bib38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"05","key":"10.1016\/j.chest.2026.04.040_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.23822\/EurAnnACI.1764-1489.94","article-title":"Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study","volume":"51","author":"Kurosawa","year":"2019","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.chest.2026.04.040_bib40","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.chest.2026.04.040_bib41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/cea.14489","article-title":"Role of IL-5 in asthma and airway remodelling","volume":"54","author":"AbuJabal","year":"2024","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.chest.2026.04.040_bib42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.chest.2026.04.040_bib43","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"issue":"33","key":"10.1016\/j.chest.2026.04.040_bib44","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226006136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226006136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:41:35Z","timestamp":1791463295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226006136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0012369226006136"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.04.040","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Clinical Response to Benralizumab Using CT Imaging","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}